NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization494.97 mln
Float14.60 mln
Earnings Date07/30/2026
1-Year Forecast
31.00
Transformational upside
Relative Strength
26
/ 100
Underperforming
Debt / Equity
0.01
Debt-free
ROE
-101
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Crescent Biopharma is a US-based cancer drug development company founded in 2024 and based in Waltham, Massachusetts. Its most advanced drug candidate, CR-001, is currently in Phase 3 clinical trials as a treatment for solid tumors, with two additional candidates, CR-002 and CR-003, also in development. The company works alongside Sichuan Kelun-Biotech to bring new cancer treatments to market.
